Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

Qilu Pharmaceutical is the lead sponsor of 52 current clinical trials in our China and EU (CTIS) registers. 36 are recruiting patients now. The most common phase is Phase 3. The drugs named most often in its trials are Iparomlimab and Tuvonralimab, QLC5508 and Gemcitabine. The most-studied condition is Advanced Solid Tumor.

ClinicalTrials.gov trials by status

Recruiting3671%
Not yet open1224%
Active, closed24%
By invitation12%

Trials by phase

Phase 32039%
Phase 11427%
Phase 1/2714%
Phase 2612%
Phase 2/324%
Phase 424%

Clinical trials sponsored by Qilu Pharmaceutical

51 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
Phase I Study of QLC5508 in Advanced Solid Tumors: C-QTc, Pharmacokinetics (PK) Comparisons and Drug-drug Interaction NCT07620041 · ClinicalTrials.gov ↗ · Refractory or Relapsed Solid Tumors Drugs: Darolutamide, Itraconazole, QLC5508	Phase 1	Recruiting	2026-06	China
A Phase 3 Clinical Study of QL2106 Injection NCT07511647 · ClinicalTrials.gov ↗ · Plaque Psoriasis Drug: Tremfya	Phase 3	Recruiting	2026-06	China
Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in Carbapenem-Resistant Enterobacteriaceae Infections NCT07089186 · ClinicalTrials.gov ↗ · Hospital-acquired Bacterial Pneumonia (HABP), Ventilator-associated Bacterial Pneumonia (VABP), Complicated Intra-abdominal Infection (cIAI) Drug: Meropenem and Pralurbactam	Phase 3	Recruiting	2025-04	China
Study of MHB088C for Patients With Advanced Solid Malignant Tumors NCT07102004 · ClinicalTrials.gov ↗ · Advanced/Metastatic Solid Tumors Drug: MHB088C	Phase 1/2	Recruiting	2023-06	China
A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLC NCT06754644 · ClinicalTrials.gov ↗ · NSCLC Drugs: Carboplatin, Pembrolizumab, Pemetrexed	Phase 3	Recruiting	2025-01	China
QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma NCT07463573 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma (ESCC) Drugs: Irinotecan Hydrochloride, QLC5508	Phase 3	Recruiting	2026-04	China
A Study of QLP2117 in Combination With QL2107 in Advanced Solid Tumor Patients NCT06911827 · ClinicalTrials.gov ↗ · Advanced Solid Tumor Drug: QL2107	Phase 1/2	Recruiting	2025-05	China
A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma NCT07138209 · ClinicalTrials.gov ↗ · Relapsed or Refractory Multiple Myeloma Drugs: Dexamethasone, Pomalidomide, QLS32015	Phase 3	Recruiting	2025-11	China
Phase I Clinical Study of QLS-1304 in the Treatment of Patients With Advanced Malignant Tumors NCT06823609 · ClinicalTrials.gov ↗ · Advanced Malignant Tumor Drug: QLS1304	Phase 1	Recruiting	2025-03	China
A Study to Compare QLS31905 and Chemotherapy With Placebo and Chemotherapy in Participants With Pancreatic Cancer NCT07079228 · ClinicalTrials.gov ↗ · Pancreatic Cancer Drugs: Gemcitabine, Nab-paclitaxel, QLS31905	Phase 3	Recruiting	2025-09	China
A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer NCT06954246 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer Extensive Stage Drugs: Irinotecan, MHB088C, Paclitaxel	Phase 3	Recruiting	2025-06	China
Compare the Efficacy and Safety of QL0605 Injections at Different Timepoints NCT06616571 · ClinicalTrials.gov ↗ · Chemotherapy-Induced Febrile Neutropenia Drug: PEG-rhG-CSF	Phase 4	Recruiting	2024-09	China
QL0911 for the Treatment of Cancer Treatment-Induced Thrombocytopenia NCT06456528 · ClinicalTrials.gov ↗ · Cancer Treatment-Induced Thrombocytopenia	Phase 2/3	Recruiting	2024-10	China
GM1 Prophylaxis for Nab-paclitaxel-associated Chemotherapy-induced Peripheral Neuropathy (CIPN) in Patients With Breast Cancer NCT06994507 · ClinicalTrials.gov ↗ · Chemotherapy-induced Peripheral Neuropathy (CIPN)	Phase 3	Recruiting	2025-08	China
A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer NCT06383767 · ClinicalTrials.gov ↗ · Metastatic Breast Cancer	Phase 3	Recruiting	2024-07	China
A Study to Evaluate the Efficacy and Safety of Meropenem and Pralurbactam in HABP/VABP NCT07327619 · ClinicalTrials.gov ↗ · Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia Drugs: Ceftazidime-avibactam, Meropenem and Pralurbactam	Phase 3	Recruiting	2026-01	China
A Comparative Study to Valuating the Efficacy and Safety of QL1206 and Prolia® NCT07062978 · ClinicalTrials.gov ↗ · Postmenopausal Women With Osteoporosis at High Risk of Fracture Drug: Prolia	Phase 3	Recruiting	2025-06	China
Efficacy and Safety Study of QLM3003 Ointment in Participants With Mild or Moderate Atopic Dermatitis NCT06880276 · ClinicalTrials.gov ↗ · Atopic Dermatitis	Phase 3	Recruiting	2025-05	China
A Study Evaluates the Safety, Pharmacokinetics, Immunogenicity and Efficacy of QLS31903 in Advanced Solid Tumor Patients NCT05823285 · ClinicalTrials.gov ↗ · Advanced Solid Tumors	Phase 1	Recruiting	2023-03	China
A Phase 3 Clinical Study of QLM3004 in Delaying Myopia in Children NCT06151587 · ClinicalTrials.gov ↗ · Myopia	Phase 3	Recruiting	2023-08	China
A Study of Neoadjuvant QL1706 in Participants With Untreated dMMR/MSI-H Resectable Colon Cancer NCT06686576 · ClinicalTrials.gov ↗ · Colon Cancer Drug: Iparomlimab and Tuvonralimab	Phase 3	Recruiting	2024-12	China
QLS5212 for Participants With Advanced Solid Tumors NCT07467629 · ClinicalTrials.gov ↗ · Solid Tumor Cancer	Phase 1	Recruiting	2026-05	China
A Phase I Study of QLS2309 Injection in Patients With CD70+ Relapsed/Refractory Hematologic Malignancies NCT07173595 · ClinicalTrials.gov ↗ · Relapsed or Refractory Hematologic Malignancies	Phase 1	Recruiting	2025-12	China
A Study of CEND-1 With Chemotherapy as First-Line Therapy in Patients With Pancreatic Ductal Adenocarcinoma NCT06261359 · ClinicalTrials.gov ↗ · Pancreatic Ductal Adenocarcinoma (PDAC) Drugs: Gemcitabine, Nab-paclitaxel	Phase 2	Recruiting	2024-03	China
Phase II Study of QLC2519 in Pediatric Solid Tumor Participants NCT07724756 · ClinicalTrials.gov ↗ · Pediatric Malignant Solid Tumor, Febrile Neutropenia (FN), Neutropenia	Phase 2	Recruiting	2026-06	China
A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors NCT07256782 · ClinicalTrials.gov ↗ · Advanced Solid Tumor Drugs: Cisplatin/carboplatin, Iparomlimab and Tuvonralimab, Ivonescimab	Phase 1/2	Recruiting	2025-10	China
Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids NCT06671548 · ClinicalTrials.gov ↗ · Heavy Menstrual Bleeding, Uterine Fibroids Drug: Relugolix	Phase 3	Recruiting	2024-01	China
Assess the Plasma, Epithelial Lining, and Alveolar Macrophage Concentrations of Intravenous Meropenem-Pralubactam (Meropenem/FL058) in China Healthy Adult Participants NCT07124468 · ClinicalTrials.gov ↗ · Infections	Phase 1	Recruiting	2025-09	China
A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection. NCT05487391 · ClinicalTrials.gov ↗ · Carcinoma, Non-Small-Cell Lung	Phase 3	Recruiting	2022-12	China
A Phase I Clinical Study of QLC1101 in Patients With Advanced Solid Tumors NCT06403735 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer	Phase 1	Recruiting	2024-04	China
Phase Ib/II Clinical Study of QLS1304 Combined With Endocrine Therapy in the Treatment of ER+/HER2- Breast Cancer Patients NCT07235176 · ClinicalTrials.gov ↗ · Advanced ER+/HER2- Breast Cancer Drugs: CDK4/6i, Fulvestrant, Fulvestrant/AI	Phase 1/2	Recruiting	2026-01	China
A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer NCT07198633 · ClinicalTrials.gov ↗ · Advanced Prostate Cancer Drugs: Abiraterone acetate, Enzalutamide, QLC5508	Phase 1/2	Recruiting	2025-11	China
To Evaluate the Efficacy and Safety of Tafamidis Meglumine Soft Capsules in the Treatment of Adult Patients With Transthyretin Amyloid Polyneuropathy NCT06940336 · ClinicalTrials.gov ↗ · Transthyretin Amyloid Polyneuropathy	Phase 4	Recruiting	2025-06	China
Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma NCT07018050 · ClinicalTrials.gov ↗ · Relapsed or Refractory Multiple Myeloma Drugs: Bortezomib, Daratumumab, Dexamethasone	Phase 2	Recruiting	2025-09	China
A Study of QLG1074 Combined With Background Therapy in Subjects With Active Lupus Nephritis NCT06406205 · ClinicalTrials.gov ↗ · Lupus Nephritis	Phase 3	Recruiting	2023-12	China
A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer NCT06732323 · ClinicalTrials.gov ↗ · Triple-Negative Breast Cancer (TNBC)	Phase 3	Recruiting	2025-09	China
Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of QLS2319 in Healthy Subjects and Cancer Cachexia NCT07735104 · ClinicalTrials.gov ↗ · Cancer Cachexia Syndrome, Cancer Cachexia	Phase 1/2	Not yet open	2026-09	China
Study of QLS31905 and/or QL1706 Combination With Chemotherapy in the Advanced Malignant Solid Tumors NCT06446388 · ClinicalTrials.gov ↗ · Advanced Solid Tumor Drugs: Capecitabine, Cisplatin, Gemcitabine	Phase 2	Not yet open	2024-06	China
A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma NCT05976568 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma Drugs: Bevacizumab, Capecitabine, Iparomlimab and Tuvonralimab	Phase 2/3	Not yet open	2023-09	China
Pharmacokinetics and Pharmacodynamics Study NCT07074236 · ClinicalTrials.gov ↗ · Primary Hypercholesterolemia or Combined Hyperlipidemia Characterized by Elevated LDL-C	Phase 1	Not yet open	2025-07	China
A Study of QLS2404 Injection in Healthy Participants and Participants With Rheumatic Autoimmune Diseases NCT07751315 · ClinicalTrials.gov ↗ · Systemic Lupus Erythematosus, Primary Sjögren's Syndrome	Phase 1	Not yet open	2026-08	China
Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in CIAI NCT06633718 · ClinicalTrials.gov ↗ · Intra-abdominal Infections	Phase 3	Not yet open	2024-10	China
Phase II Clinical Study on the Efficacy and Safety of QLS7305 in Patients With Kidney Disease (Part A) NCT07730632 · ClinicalTrials.gov ↗ · IgAN - IgA Nephropathy, Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN), C3 Glomerulopathy (C3G)	Phase 2	Not yet open	2026-08	China
A Study of QLS4131 in Patients With Recurrent or Refractory Multiple Myeloma NCT06500507 · ClinicalTrials.gov ↗ · Relapsed or Refractory Multiple Myeloma Drug: QLS4131	Phase 1	Not yet open	2024-08	China
Phase 1 Clinical Study of QLS5132 Monotherapy in Advanced Solid Tumors NCT06932094 · ClinicalTrials.gov ↗ · Advanced Solid Tumors	Phase 1	Not yet open	2025-05	China
A Phase I Trial of QLS1410 in Healthy Chinese Adults and Participants With Mild Essential Hypertension NCT07152444 · ClinicalTrials.gov ↗ · Uncontrolled Hypertension	Phase 1	Not yet open	2025-09	China
A Phase I Trial of QLS2313 Injection in Relapsed/Refractory Hematological Malignancies NCT07294300 · ClinicalTrials.gov ↗ · Relapsed/Refractory Hematological Malignancies	Phase 1	Not yet open	2026-01	China
A Study of QLS5133 Monotherapy in Advanced Solid Tumors NCT07061639 · ClinicalTrials.gov ↗ · Advanced Solid Tumors	Phase 1/2	Not yet open	2025-07	China
QLS1410 in Participants With Uncontrolled Hypertension NCT07489612 · ClinicalTrials.gov ↗ · Hypertension (HTN)	Phase 2	By invitation	2026-04	China
Study on the Pharmacokinetics and Safety of QL1012D and Gonal-F® in Healthy Female Volunteers NCT06864793 · ClinicalTrials.gov ↗ · Infertility, Female Drug: Gonal-F	Phase 1	Active, closed	2025-04	China
A Study of QL1706 in Combination With Chemotherapy in PD-L1-Negative Non-small Cell Lung Cancer NCT05690945 · ClinicalTrials.gov ↗ · Lung Cancer Drug: Iparomlimab and Tuvonralimab	Phase 3	Active, closed	2023-02	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Qilu Pharmaceutical in the EU trials register (CTIS)

1 trial

Authorised or ongoing trials in the EU Clinical Trials Information System with Qilu Pharmaceutical as sponsor. Some are the same study as a ClinicalTrials.gov record above; the two registries share no common ID. Trials with a site in Ireland are listed first.

Study	Phase	Status	Countries
A Phase 1, Randomized, Double-Blind, Two-Arm, Two-Way Crossover Study of Pharmacokinetics and Pharmacodynamics of QL0911 2025-523355-59-00 · CTIS ↗ · Hemic and Lymphatic Diseases	Phase 1	Ongoing	Poland

Drugs in Qilu Pharmaceutical trials

45 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

+ 5 more in the trial list above.

Conditions in Qilu Pharmaceutical trials

58 conditions

Advanced Solid Tumor3 Relapsed or Refractory Multiple Myeloma3 Advanced Solid Tumors3 Pancreatic Cancer2Refractory or Relapsed Solid Tumors1Hypertension (HTN)1Plaque Psoriasis1Hospital-acquired Bacterial Pneumonia (HABP)1Ventilator-associated Bacterial Pneumonia (VABP)1Complicated Intra-abdominal Infection (cIAI)1Complicated Urinary Tract Infection (cUTI)1Advanced/Metastatic Solid Tumors1Cancer Cachexia Syndrome1Cancer Cachexia1NSCLC1 Esophageal Squamous Cell Carcinoma (ESCC)1 Hepatocellular Carcinoma1Primary Hypercholesterolemia or Combined Hyperlipidemia Characterized by Elevated LDL-C1Systemic Lupus Erythematosus1Primary Sjögren's Syndrome1Advanced Malignant Tumor1Small Cell Lung Cancer Extensive Stage1Chemotherapy-Induced Febrile Neutropenia1Cancer Treatment-Induced Thrombocytopenia1

By trial register

Register	Trials	Recruiting
Clinical trials in China	51	36
EU register (CTIS)	1	—

A trial with sites in more than one country appears in each of those registers.

Other sponsors in Advanced Solid Tumor

Sponsor	Trials
BeOne Medicines	11
Daiichi Sankyo	7
TORL Biotherapeutics	5
OncoC4	5
LaNova Medicines	5
MediLink Therapeutics (Suzhou)	4
Suzhou Zelgen Biopharmaceuticals	4
BioNTech	3
EMD Serono Research & Development Institute	3
Hansoh BioMedical R&D Company	3

Sponsors with the most current trials registered for this condition.

Questions about Qilu Pharmaceutical trials

How many clinical trials does Qilu Pharmaceutical sponsor?

Qilu Pharmaceutical is the lead sponsor of 51 current trials on ClinicalTrials.gov in our China register, and 1 authorised or ongoing trial in the EU register (CTIS), as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Qilu Pharmaceutical trials recruiting?

Yes. 36 of its 51 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Qilu Pharmaceutical testing?

Its current trials name 45 drugs and biologicals as interventions. The most frequent are Iparomlimab and Tuvonralimab (5), QLC5508 (4), Gemcitabine (3), Oxaliplatin (3) and QL2107 (3). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Qilu Pharmaceutical clinical trials